Cite
MLA Citation
R Panaccione et al.. “P433 Efficacy of risankizumab by baseline clinical, biochemical, and endoscopic disease severity in moderately to severely active Crohn's disease.” Journal of Crohn's and colitis, vol. 17, n.d., p. i560. http://access.bl.uk/ark:/81055/vdc_100179866730.0x00001c